Porcine Secretin

NDA 21209, held by Chirhoclin. Porcine Secretin.

As of Nov 14, 2026, NDA 21209 (Porcine Secretin), held by Chirhoclin, was first approved by FDA on Apr 4, 2002, with 2 approved supplements and 0 published complete response letters.

First approved: Apr 4, 2002
Review: Priority
Supplements approved: 2
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 3 submissions below

Date	Submission	Status	Documents
Apr 4, 2002	Original applicationTYPE 6 · Priority review	Approved	None posted

Products

2 strengths and forms


Porcine Secretin16MCG · injectable;subcutaneous lyophilized power	Porcine Secretin	Rx
Porcine Secretin40MCG · injectable;subcutaneous lyophilized power	Porcine Secretin	Rx

All 3 submissions, including labeling and manufacturing supplements


Oct 26, 2016	Supplement 2Labeling · Standard review	Approved	Label
Oct 26, 2016	Supplement 1Labeling · Standard review	Approved	None posted
Apr 4, 2002	Original applicationTYPE 6 · Priority review	Approved	None posted

Identifiers

Application: NDA 21209
Drugs@FDA: Overview at FDA
Company: Chirhoclin

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters